Thermo Fisher and Janssen Team Up on Cancer Diagnostic
Thermo Fisher and Janssen have agreed to work together to develop an oncology companion diagnostic.
The two companies will collaborate on research and development to validate multiple biomarkers for use with Thermo Fisher’s Oncomine Dx target test, which is being designed to identify patients for enrollment in non-small cell lung cancer clinical trials.
Oncomine Dx is a next-generation sequencing assay that contains 46 cancer-related biomarkers. It features a fast turnaround time and ”the lowest sample requirements on the market for detection of both DNA and RNA variants,” according to Thermo Fisher.